Current News

Contact | Print version | Send article | RSS feed

Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu

23 Feb 2006 - Novartis and Alnylam Pharmaceuticals, Inc. announced that they have formed a new collaboration to develop RNAi therapeutics for pandemic flu. This collaboration is in addition to the collaboration formed by the two companies in September 2005, and significantly reinforces the development program for pandemic flu announced by Alnylam in December 2005. In the newly formed collaboration, Alnylam and Novartis will advance RNAi therapeutics for pandemic flu to initial clinical testing and, if successful, regulatory approval. This new alliance leverages Alnylam's expertise in RNAi and Novartis' capabilities and experience in bringing innovative therapeutics to patients. Financial terms were not disclosed.